ストックスクリーナーアプリを入手
1.39
10.55%
0.11
アフターアワーズ：
1.38
-0.01
-0.72%
Lucid Diagnostics Inc (LUCD) 最新ニュース
Blue Cross Blue Shield backs esophageal cancer DNA test By Investing.com - Investing.com Australia
Blue Cross Blue Shield backs esophageal cancer DNA test - Investing.com India
Lucid Diagnostics Secures First Positive Commercial Insurance Coverage Policy for its EsoGuard® Esophageal DNA Test - PR Newswire
Lucid Diagnostics Executes First Concierge Medicine Contract wit - GuruFocus.com
Lucid Diagnostics Regains Compliance with Nasdaq Minimum Bid Pri - GuruFocus.com
PAVmed CEO to Reveal Growth Strategy and Q4 Results in Upcoming Investor Call - StockTitan
Lucid Diagnostics (NASDAQ:LUCD) Trading Down 14.4% – Here’s Why - Defense World
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 24, 2025 - BioSpace
Analyzing Embecta (NASDAQ:EMBC) and Lucid Diagnostics (NASDAQ:LUCD) - Defense World
Understanding Lucid Diagnostics Inc (NASDAQ: LUCD)’s Growth Potential - Stocks Register
Midtown company tells investors esophageal pre-cancer screening should be an easier pill to swallow - Crain's New York Business
Lucid Diagnostics secures $15.3 million in stock offering By Investing.com - Investing.com Australia
Lucid Diagnostics Announces Closing of $15.3 Million Registered Direct Offering - GuruFocus.com
Lucid Diagnostics secures $15.3 million in stock offering - Investing.com India
Lucid Diagnostics Raises $15.3 Million in Stock Offering - TipRanks
Has Lucid Diagnostics Secured Enough Capital? $15.3M Raised at $1.10 Per Share - StockTitan
Lucid Diagnostics secures $15.3 million in stock sale By Investing.com - Investing.com Australia
Lucid Diagnostics Announces $15.3 Million Registered Direct Offering - The Eastern Progress Online
SEC Form 424B5 filed by Lucid Diagnostics Inc. - Quantisnow
Lucid Diagnostics announces registered direct offering - Medical Buyer
Lucid Diagnostics Announces $15.3 Million Registered Direct Offe - GuruFocus.com
Lucid Diagnostics Announces $15.3 Mln Direct Offering - Nasdaq
Lucid Diagnostics ends "at the market" equity offering By Investing.com - Investing.com South Africa
Lucid Diagnostics stock dips on $15.3M share offering - MSN
Lucid Diagnostics secures $15.3 million in stock sale - Investing.com India
Lucid Diagnostics Prices $15.3 Million Direct Offering -March 04, 2025 at 09:03 am EST - Marketscreener.com
Lucid Diagnostics Announces $15.3 Million Direct Offering - TipRanks
Lucid Diagnostics ends "at the market" equity offering - Investing.com India
Lucid Diagnostics to sell 13.94M shares at $1.10 in registered direct offering - TipRanks
Lucid Diagnostics Raises $15.3 Million Through Common Stock Offering at $1.10 Per Share - StockTitan
Can Lucid's Cancer Test Reach Millions More Patients? NIH Invests $8M to Find Out - StockTitan
Renowned Investigators Awarded $8 Million NIH Grant to Study Lucid Diagnostics' EsoGuard® in At-Risk Patients without Symptomatic GERD - The Malaysian Reserve
Lucid Diagnostics meets Nasdaq minimum bid price rule By Investing.com - Investing.com Australia
Lucid Diagnostics Restores Nasdaq Listing Compliance - Nasdaq
Lucid Diagnostics regains compliance with Nasdaq listing requirement - MSN
Lucid Diagnostics meets Nasdaq minimum bid price rule - Investing.com
Lucid Diagnostics Regains Compliance with Nasdaq Minimum Bid Price Requirement - PR Newswire
Lucid Diagnostics Executes First Concierge Medicine Contract with LEAA Health -February 20, 2025 at 08:31 am EST - Marketscreener.com
Lucid Diagnostics secures concierge medicine contract By Investing.com - Investing.com Nigeria
LUCDLucid Diagnostics Inc. Latest Stock News & Market Updates - StockTitan
Lucid Diagnostics secures concierge medicine contract - Investing.com
Lucid Diagnostics Executes First Concierge Medicine Contract with LEAA Health - Nasdaq
Lucid Diagnostics Executes First Concierge Medicine Contract with LEAA Health – Company Announcement - Financial Times
PAVmed regains compliance with Nasdaq Capital Market’s CLS - Medical Buyer
PAVMPavmed Latest Stock News & Market Updates - StockTitan
Innovative Tech Company Surges Forward: PAVmed Triumphs in Nasdaq Compliance - Smartphone Magazine
Navigating the High Seas of Market Compliance: PAVmed’s Resilient Return - Mi Valle
PAVmed Triumphs on Nasdaq: A Medical Tech Comeback Story - Jomfruland.net
Critical Victory: PAVmed's Strategic Moves Save Nasdaq StatusFull Details Inside - StockTitan
SI-BONE (NASDAQ:SIBN) vs. Lucid Diagnostics (NASDAQ:LUCD) Head to Head Survey - Defense World
Lucid Diagnostics stock hits 52-week high at $1.5 amid growth optimism - MSN
Lucid Diagnostics (NASDAQ:LUCD) vs. Insulet (NASDAQ:PODD) Head-To-Head Review - Defense World
2.18%
大文字化:
|
ボリューム (24 時間):